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Abstract
Background: Recently, the use of hypo-fractionated treatment schemes for the prostate cancer
has been encouraged due to the fact that α/β ratio for prostate cancer should be low. However a
major concern on the use of hypofractionation is the late rectal toxicity, it is important to be able
to predict the risk of toxicity for alternative treatment schemes, with the best accuracy. The main
purpose of this study is to evaluate the response of rectum wall to changes in fractionation and to
quantify the α/β ratio for late rectal toxicity
Methods: 162 patients with localized prostate cancer, treated with conformal radiotherapy, were
enrolled in a phase II randomized trial. The patients were randomly assigned to 80 Gy in 40
fractions over 8 weeks (arm A) or 62 Gy in 20 fractions over 5 weeks (arm B). The median follow-
up was 30 months. The late rectal toxicity was evaluated using the Radiation Therapy Oncology
Group (RTOG) scale. It was assumed ≥ Grade 2 (G2) toxicity incidence as primary end point. Fit
of toxicity incidence by the Lyman-Burman-Kutcher (LKB) model was performed.
Results: The crude incidence of late rectal toxicity ≥ G2 was 14% and 12% for the standard arm
and the hypofractionated arm, respectively. The crude incidence of late rectal toxicity ≥ G2 was
14.0% and 12.3% for the arm A and B, respectively. For the arm A, volumes receiving ≥ 50 Gy (V50)
and 70 Gy (V70) were 38.3 ± 7.5% and 23.4 ± 5.5%; for arm B, V38 and V54 were 40.9 ± 6.8% and
24.5 ± 4.4%. An α/β ratio for late rectal toxicity very close to 3 Gy was found.
Conclusion: The ≥ G2 late toxicities in both arms were comparable, indicating the feasibility of
hypofractionated regimes in prostate cancer. An α/β ratio for late rectal toxicity very close to 3
Gy was found.
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Background
During the last years a wide consensus has been growing
on the fact that α/β ratio for prostate cancer should be low
[1-6], encouraging the use of hypo-fractionated treatment
schemes. This would result in an increased therapeutic
ratio besides a well known series of practical advantages,
like diminishing the number of accesses to department,
shorter treatment time and abatement of waiting lists.
Due to the fact that a major concern on the use of hypof-
ractionation is the late rectal toxicity, the necessity to pre-
dict the risk of toxicity for alternative treatment schemes is
becoming insistent. Leborgne [7], in a study conducted on
patients treated with brachytherapy for cancer of the cer-
vix, evaluated an α/β ratio for rectal late complications
not significantly different from 3 Gy. In a more recent
publication, Brenner [8] underlined the importance of
investigating the sensitivity of late rectal damage to
changes in fractionation and encouraged the use of new
data from hypofractionated schemes. His analysis resulted
in an α/β ratio estimate of 5.4 Gy, suggesting a correlation
with early-responding damage.
Since 2003, a phase II randomized trial started at our insti-
tute, to compare a conventional versus a hypofractionated
treatment scheme for localized prostate cancer. It was
assumed an α/β ratio for prostate of 1.5 Gy. The primary
objective of the trial were acute and late toxicity, and sur-
vival and local control with controlled PSA (Prostate Spe-
cific Antigen). In this work, dose-volume data of rectal
wall from patients treated exclusively at our institution
were fitted to the Normal Tissue Complication Probability
(NTCP) model proposed by Lyman-Kutcher-Burman [9-
11]. The effect of dose fractionation was included in the
model to quantify the α/β ratio for late rectal toxicity.
Methods
Patient population
From March 2003 to June 2008, 162 patients with carci-
noma of the prostate were randomised for the present
study. Assuming that an incidence of ≥ Grade 2 (G2) tox-
icity in less than 55% of patients is acceptable, the sample
size was calculated for a power of 80% and a level of sig-
nificance of 5%. A total of 114 patients, having a follow-
up longer than 6 months, were included in the present
analysis: 57 patients in each arm. All patients enrolled in
this trial were younger than 85 with high risk prostatic car-
cinoma, that is at least two of the following risk factors
present: T2c-T4, PSA > 10 ng/ml, Gleason score 710.
Other eligibility criteria were no nodes involvement
present at Computer Tomography (CT) or Magnetic Reso-
nance imaging, no other previous radiotherapy (RT) or
prostatectomy, no other malignant disease except for
Basal cell carcinoma (BCC) or other tumors in the past
five years, informed consent.
Patients received hormonal treatment (HT), in addition to
RT, two months before; Casodex (non-steroidal anti-
androgen) was administered for 270 days, Zoladex (anal-
ogous Goserelin) was started 7 days after the start of Caso-
dex and was administered at the 7th, 97th and 187th day.
The clinical and pathological features of the two groups of
patients are reported in Table 1. The baseline recorded
characteristics were age, initial PSA values (≤ 10, between
11 and 20 and > 20 ng/mL), stage (<T2c vs. ≥ T2c), and
Gleason score (≤ 6 vs. > 6). The differences between
groups were tested using chi-square.
Contouring, planning and treatment
The clinical target volume (CTV) was the prostatic gland
and the seminal vescicles; the planning target volume
(PTV) was obtained by expanding CTV with a margin of 1
cm in each direction, and of 0.6 cm posteriorly. Rectum
was manually contoured from the distal ischiatic branch
to the sigmoid flexure as a hollow organ, i.e. rectal wall. In
addition bladder wall and femoral heads were contoured.
Dose calculations were performed using the treatment
planning system Eclipse (Release 6.5, Varian Associates,
Palo Alto, CA), to deliver the prescribed dose to the Inter-
national Commission on Radiation Units and Measure-
ments (ICRU) reference point [12], with a minimum dose
of 95% and a maximum dose of 107% to the PTV.
Dose-volume constraints on rectal wall were: no more
than 30% of rectal wall receiving more than 70 Gy (V70)
and no more than 50% of rectal wall receiving more than
50 Gy (V50) for the conventional arm; no more than 30%
of rectal wall receiving more than 54 Gy (V54) and no
more than 50% of rectal wall receiving more than 38 Gy
(V38) for the hypo-fractionated arm. Dose-volume con-
Table 1: Clinical and pathological features of the two patients 
populations
Characteristics Arm A Arm B p value
Age 0,922
< 70 8 7
7175 23 22
> 75 26 28
Stage 1,000
<T2c 27 26
≥ T2c 30 31
Gleason Score 0,392
≤ 69 5
> 6 48 52
initial PSA 0,400
≤ 10 18 14
1120 20 17
> 20 19 26Journal of Experimental & Clinical Cancer Research 2009, 28:117 http://www.jeccr.com/content/28/1/117
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straints on bladder wall were: V70 less than 50% for the
conventional arm and V54 less than 50% for the hypo-frac-
tionated arm. Maximum dose on femoral head was,
whenever achievable, less than 55 Gy and 42 Gy for arm
A and arm B, respectively. Safer dose volume constraints
in the hypofractionation arm were intentionally chosen;
that is as if the equivalence was calculated with an α/β
value lower than 3 Gy.
Treatment plans were designed with a 3DCRT (three
dimensional conformal radiation therapy) six field tech-
nique, with gantry angles: 45°, 90°, 135°, 225°, 270°,
315°. The two posterior-oblique fields had 45° wedges
and all fields were conformed with a multileaf collimator
(MLC). Treatments were delivered with 15 MV photon
beam generated by a Clinac 2100 CD Varian accelerator,
equipped with Millennium MLC (120 leaves).
Toxicity evaluation
Rectal toxicity was assessed using the Radiation Therapy
Oncology Group (RTOG) scale [13], every six months for
the first three years after the end of treatment and after-
wards every year. The incidence of ≥ G2 late rectal toxicity
as a function of time (months from the end of treatment)
was evaluated by Kaplan-Meier curves using MedCalc soft-
ware (Version 8.1.0.0, Mariakerke, Belgium). The log rank
test was performed to establish if any statistically signifi-
cant difference exists between the two arms.
Radiobiologic calculations
Cumulative dose-volume histograms (DVHs) have been
first evaluated for the two arms, independently. Then, to
compare the two different treatment schemes, DVHs for
both arms have been corrected converting the physical
dose in the i-th volume fraction to the biologically equiv-
alent total dose normalized to the standard fraction of 2
Gy (NTD2), as described in appendix 1 (A.5).
The Lyman-Burman-Kutcher (LKB) model was used to
predict the NTCP for late rectal toxicity. The ≥ G2 late rec-
tal toxicity was assumed as primary end point in the NTCP
calculations. The original model parameters are n, m and
TD50  and they determine the volume dependence of
NTCP, the slope of NTCP vs. dose and the tolerance dose
to the whole organ leading to a 50% complication proba-
bility, respectively (appendix 1). The α/β parameter was
then introduced in the model by the NTD2 to take into
account for altered fractionaction schemes, as illustrated
also by other authors [14,15].
At first, the values n = 0.12, m = 0.15 estimated by Burman
et al. [10] and the value TD50 = 80 Gy evaluated by Emami
et al. [16] were involved in the calculation of the NTCP
distributions for conventional and hypofractionated
arms.
To minimize the deviation between the clinical and the
predicted complication incidences, the best parameters
estimation of the model was performed by the maximum
likelihood method [17]. For binomially distributed data
such as the NTCP data, the log-likelihood for the entire
data set is given by:
where N is the total number of patients, Ri is equal to 1 for
patients who did experience ≥ G2 late rectal toxicity or 0
for patients who did not.
The optimization of all the four model parameters was
initially run but, because of the large resulting 95% confi-
dence intervals (CI) due to the limited number of patients
experiencing  ≥ G2 late toxicity, the results were not
reported. Consequently, it was decided to reduce the
number of degrees of freedom by keeping fix the n and m
parameters at the original values proposed by Burman et
al. [10]. This choice was motivated by the fact that these
values, even if obtained assuming as end point severe
proctitis, necrosis, stenosis or fistula, resulted hardly dif-
ferent from those reported in more recent studies of late
rectal toxicity modeling [18,19], in which similar end
points to that considered in the present work were
assumed. Moreover, this choice is in accordance with our
belief that rectal bleeding is most strongly influenced by
high dose levels (low n value) [20].
The 95% CI of the estimated TD50 and α/β parameters
were established by the profile likelihood method as
described by other authors [21]. All the calculations were
performed by using the Matlab code (Release 6.5, The
Mathworks Inc., Natick, Massachusetts).
Results
DVH analysis
Differential and cumulative dose-volume histograms of
each patient were collected. For both arms dose-volume
constraints were well satisfied: for arm A, V50 and V70
resulted 38.3 ± 7.5% and 23.4 ± 5.5%, respectively; for
arm B, V38 and V54 resulted 40.9 ± 6.8%. and 24.5 ± 4.4%,
respectively (Fig. 1). From the small standard deviation of
V50/V70 and V38/V54, it can be inferred that all patients
were almost equally treated among each arm with respect
to the dose distribution of the rectal wall.
To compare the two different treatment schemes, DVHs
for the two arms have been both normalized, converting
the physical dose in each volume fraction to the NTD2
(A.5) supposing an α/β ratio of 3 Gy. The plot in Fig. 2
shows together the corrected DVHs for the two arms: the
two curves are very close to each other, suggesting the
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equivalence of the conventional and the hypofractionated
schemes in terms of the expected ≥ G2 late rectal toxicity.
Incidence of late toxicity
The crude incidence ≥ G2 late rectal toxicity was 14.0% (8
patients) and 12.3% (7 patients) for the conventional and
the hypo-fractionated arm respectively, after a median fol-
low up of 30 months for both arms (range: 661 months
for arm A, 663 months for arm B). In arm A, three patients
experienced G3 toxicity and no patient developed G4;
while in arm B no patients had late toxicity higher than
G2. The actuarial ≥ G2 late toxicity at 30 months were
(a) The average with its standard deviation of the distribution  of the cumulative rectal wall DVHs for the conventional arm Figure 1
(a) The average with its standard deviation of the dis-
tribution of the cumulative rectal wall DVHs for the 
conventional arm. (b) The average with its standard devia-
tion of the distribution of the cumulative rectal wall DVHs 
for the hypofractionated arm.
The averages of the distributions of the normalized cumula- tive rectal wall dose-volume-histograms for arm A (dashed  line) and for arm B (solid line) Figure 2
The averages of the distributions of the normalized 
cumulative rectal wall dose-volume-histograms for 
arm A (dashed line) and for arm B (solid line). NTD2 
on the X-axis indicates the biologically equivalent total dose 
normalized to the standard fraction of 2 Gy, supposing an α/
β ratio of 3 Gy.
Actuarial incidence of ≥ Grade 2 late rectal toxicity versus  months after radiotherapy (mo.), for arm A and B Figure 3
Actuarial incidence of ≥ Grade 2 late rectal toxicity 
versus months after radiotherapy (mo.), for arm A 
and B.Journal of Experimental & Clinical Cancer Research 2009, 28:117 http://www.jeccr.com/content/28/1/117
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13.0% and 13.5% for arm A and B, respectively, as illus-
trated by the Kaplan-Meier curves in Fig. 3. No significant
difference exists between the curves (p-value = 0.688 by
the log rank test).
NTCP modeling: optimization of TD50 and α/β
NTCP distributions were calculated for both arms to esti-
mate the probability of ≥ G2 late rectal toxicity, using the
values n = 0.12, m = 0.15, TD50 = 80 Gy and α/β = 3 Gy.
An average probability of 9.6% ± 3.3% and 5.6% ± 1.8%
were obtained for the conventional and the hypo-frac-
tionated arm, respectively.
These NTCP calculations did not result in good agreement
with the clinical outcome for both arms, indicating the
necessity to optimize the model parameters. Before the
modeling, a plot of NTCP with its standard deviation ver-
sus α/β was generated for the arms A and B to better eval-
uate the influence of α/β on the toxicity prediction (Fig.
4). The plotted NTCP values were obtained by averaging
on the entire patients population of arm A and B, sepa-
rately, the NTCP data calculated varying α/β between 0.5
and 10 Gy, at 0.1 Gy intervals. The other three parameters
were kept fix (n = 0.12, m = 0.15, TD50 = 80 Gy).
As expected, it resulted that higher values of α/β lead to an
increase of NTCP in arm A, because the effect of fraction-
ation (or the dose per fraction) weights less that the effect
of the total dose. For the same reason, the NTCP in arm B
rapidly decreases at increasing values of α/β, because the
total dose of the hypofractionated arm (62 Gy) is expected
to induce a significantly lower complication than the total
dose of the conventional arm (80 Gy). Due to the compa-
rable toxicities reported among the two arms, it is mean-
ingful to observe the plots in the region where the two
NTCP curves overlap. Also taking into account the NTCP
standard deviations, the plots suggest approximately an
α/β value between 1 and 3.5 Gy (given by the width of the
box), with a most probable value close to 2 Gy (where the
average NTCP values are coincident).
Together with α/β, the parameter TD50 was also optimized
because, as previously observed, the complication inci-
dence predicted by the model using TD50 = 80 Gy was
lower than the clinical outcome for both arms (9.6% and
5.6% against 13.0% and 13.5%, for arm A and B respec-
tively). The m and n parameters were kept fix during the
modeling, choosing the values: n = 0.12 and m = 0.15
(10), as mentioned in the Methods and materials.
The value of TD50 was decreased by the fitting process,
resulting equal to 76.0 Gy [95% CI: 72.280.5 Gy]. The
best estimate for α/β was instead 2.3 Gy [95% CI: 1.15.6
Gy]. To evaluate the goodness of fit, the observed and
expected numbers of complications (or events) were com-
pared for six NTCP groups (Table 2).
The chi-squared value, obtained as the sum of the squares
of differences between the observed and expected num-
bers of complications divided by the expected numbers of
complications, resulted 4.3. Being the chi-square value
11.07 for 5 degrees of freedom and a 5% significance
level, it cannot be rejected the hypothesis that the fit is
acceptable. NTCP values have been recalculated for the
two arms with the optimized parameters; the values of
clinical incidence fall now inside the confidence intervals
of NTCP, as shown in Table 3.
Discussion
In this work, a modeling of late rectal toxicity in patients
with localized prostate cancer was performed. The
patients were randomly assigned to receive 80 Gy in 40
fractions over 8 weeks (arm A) or 62 Gy in 20 fractions
over 5 weeks to the prostate (arm B). The comparison
between the conventional and the hypofractionated arms
allowed to evaluate the response of rectal toxicity to
changes in fractionation.
The crude rate of ≥ G2 late rectal toxicity were 14.0% and
12.3% for arm A and B respectively, thus very close to the
actuarial values at 30 months (Fig. 3), indicating that this
time can be considered adequate to report the late rectal
toxicity, as documented also by other studies [18,22,23].
The comparable toxicity rates observed in the two arms
suggest that the hypofractionated regimes in prostate can-
Plot of the average Normal Tissue Complication Probability  (NTCP) with its standard deviation (dashed lines) versus the  α/β parameter, for the arm A (black line) and B (gray line) Figure 4
Plot of the average Normal Tissue Complication 
Probability (NTCP) with its standard deviation 
(dashed lines) versus the α/β parameter, for the arm 
A (black line) and B (gray line). The other parameters 
were n = 0.12, m = 0.15 and TD50 = 80 Gy. The width of the 
box indicates the range of probable α/β values.Journal of Experimental & Clinical Cancer Research 2009, 28:117 http://www.jeccr.com/content/28/1/117
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cer are feasible, as previously reported in other studies
[24-29], though using different fractionation schemes and
end point definitions. Lukka et al. [24] compared two frac-
tionation schemes for patients with localized prostate
cancer, in a randomized trial designed to give 66 in 33
fractions or 52.5 Gy in 20 fractions to the prostate. The
authors reported similar ≥ G3 late rectal toxicity incidence
in both arms (1.3%), with a long median follow-up time
of 5.7 years. Livsey et al. [26] also analyzed bowel toxicity
in hypofractionated regime, giving to the prostate 50 Gy
in 16 fractions. The reported ≥ G2 bowel toxicity was
lower (5%), presumably due to the consistently lower
total dose.
Among all studies, the present work is best comparable to
the study of Faria et al. [29], who analyzed late rectal tox-
icity in prostate cancer patients receiving 66 Gy in 22 frac-
tions. They reported a crude incidence of ≥ G2 late rectal
toxicity of 18%, with a median follow-up time of 30
months. The deviation from our rate of toxicity probably
arise from the different total dose (66 against 62 Gy).
Assuming to prescribe to our patients of arm B 66 Gy in
22 fractions to the PTV, with the same relative dose distri-
bution to the rectal wall, the average NTCP would result
17.5 ± 4.8% with our best-fit parameters. This calculation
is in good agreement with the crude toxicity of 18% of the
study of Faria et al.[29].
The present work was undertaken with the main purpose
of quantifying the α/β ratio for ≥ G2 late rectal damage,
that still represents the dose limiting end point in prostate
radiotherapy. The rectum has been defined as rectal wall,
instead of the total rectal volume including filling, allow-
ing to improve the fit accuracy as suggested by others [21].
It was found that the best estimation for TD50 is 76.0 Gy
[72.280.5 Gy], a value slightly lower than the value of 80
Gy of Emami et al. [16] and also in agreement with a more
recent estimate proposed by Peeters et al. [19], who found
TD50 = 81 Gy (68% CI = 7590 Gy) for the same end point
and a minimum follow-up time of 3 years.
The estimated α/β = 2.3 Gy [95% CI: 1.15.6 Gy] is consist-
ent with the interval of α/β values suggested by the plot of
NTCP versus the α/β ratio illustrated in Fig. 4 and is also
consistent with the initial supposed value of 3 Gy. In fact,
assuming α/β = 3 Gy it was shown the equivalence of the
normalized cumulative rectal wall DVHs of the two arms
(Fig. 2), that suggested comparable expected toxicities as
then confirmed by our outcome data.
A value of α/β close to 3 Gy is also in accordance with the
conclusions of a study of Leborgne et al. [7], who per-
formed calculations of Biologically Effective Doses
(BEDs) in medium dose rate brachytherapy of cervix can-
cer. The authors stated that assuming α/β equal to 3 Gy for
rectal late responding tissues seems to be a provisional
value that may be of use in comparing the expected effects
of new schedules. This estimate is indeed more distant
from that one given by Brenner [8] (5.4 ± 1.5 Gy), who
made a fit of late rectal toxicity data coming from four dif-
ferent institutions, with doses per fraction between 1.8
and 3 Gy. This value, between typical α/β values for early
and late-responding tissues, would suggest that the late
rectal damage could be correlated with the very acute one,
in accordance with conclusions of other studies [30-32].
The discrepancy between these α/β estimates might be
due to differences in the underlying data. However, as
documented by the literature [33] it is a matter of debate
whether there is a real causative relationship between
acute and late rectal reactions and the question is still
open.
In the present analysis, it was decided not to take into
account the effect of rectal motion. In fact, a previous
study of our group [34] was conducted on patients treated
for prostate cancer with IMRT. The average NTCP values
showed a small variation during the radiation treatment,
if compared to those obtained from the original plan opti-
Table 2: Observed and expected numbers of complications in six NTCP groups
NTCP range No. of patients Observed Complications Expected Complications
0.050.075 11 2 1
0.0750.10 19 3 2
0.100.125 18 3 2
0.1250.15 25 2 4
0.150.175 27 4 4
0.1750.25 15 1 3
Table 3: Clinical incidence of ≥ G2 late toxicity and NTCP 
calculations
AB
Clinical incidence 14.0% 12.3%
NTCP (prior to optimization)
TD50 = 80 Gy, α/β = 3 Gy
10 ± 3% 6 ± 2%
NTCP (after optimization)
TD50 = 76 Gy, α/β = 2.3 Gy
15 ± 5% 12 ± 4%Journal of Experimental & Clinical Cancer Research 2009, 28:117 http://www.jeccr.com/content/28/1/117
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mized on the pre-treatment CT: 7.2% ± 2.9% versus 6.7%
± 2.1%, respectively. Moreover, it is reasonable to assume
that in 3DCRT these variations might be even smaller than
in IMRT, due to the less steep dose gradients across the rec-
tum.
Conclusion
In this work, a modeling of late rectal toxicity in patients
with localized prostate cancer, from a randomized phase
II study, was performed. The comparison between the
conventional and the hypofractionated arm allowed to
evaluate the response of rectal toxicity to changes in frac-
tionation. The similar rate of late toxicity in the two arms
seems to indicate the feasibility of hypofractionated
regimes in prostate cancer. Our study led to an estimation
of α/β ratio value for late rectal toxicity very close to 3 Gy;
however further prospective studies need to be performed
to definitely establish the value of the α/β ratio in a larger
cohort of patients enhancing the accuracy of the radiobio-
logical modeling.
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Appendix 1
For the LKB model [9,10], assuming a uniform irradiation
of a fraction v of the organ at dose D, NTCP can be calcu-
lated by
where t is defined as
and
As known, the parameters n, m and TD50(1) determine
the volume dependence of NTCP, the slope of NTCP vs.
dose and the tolerance dose to the whole organ leading to
a 50% complication probability, respectively.
The effective volume method [11] was chosen as histo-
gram reduction scheme for non uniform organ irradia-
tions:
where Di is the dose delivered to the volume fraction vi
and N is the number of points of the differential DVH. By
(A.4), an inhomogeneous dose distribution is converted
to an equivalent uniform irradiation of a fraction veff of the
organ at the maximum dose Dmax. Before applying the
above equations, a correction is performed to Di, to take
into account the fractionation inside each volume fraction
vi. In this way, the physical dose D in each volume fraction
v is converted to the biologically equivalent total dose
normalized to the standard fraction of 2 Gy (NTD2).
where the parameters α and β are the coefficients of the
linear and quadratic dose contributions to damage in the
linear-quadratic model of the cell survival curve and nfr is
the number of fractions.
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